The efficacy of talymus ophthalmic suspension in the treatment of ocular autoimmune disease - The efficacy of talymus ophthalmic suspension

Tsurumi University0 个研究点目标入组 30 人开始时间: 2018年10月15日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方: Tsurumi University
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The total score of the 10 clinical signs significantly decreased from baseline 2 weeks after initiating tacrolimus eye drop treatment, except at 2 months. Treatment was gradually tapered, with increasing intervals between applications. Additional medications were required to provide relief in 18 patients during follow-up. No patient discontinued treatment due to adverse drug effects. Herpes keratitis was observed in 3 cases during follow-up. However, these cases were completely controlled.

研究设计

研究类型: Interventional

入排标准

年龄范围: 8years-old 至 80years-old（—）
性别: All

入选标准

未提供

排除标准

•Subjects who doctors consider ineligible for enrollment.

研究者

发起方

Tsurumi University

相似试验

已完成

4 期

Post-marketing clinical study of TALYMUS ophthalmic suspension 0.1% (tacrolimus) in vernal keratoconjunctivitisVernal keratoconjunctivitis

JPRN-UMIN000001262Senju Pharmaceutical Co., Ltd.50

已完成

4 期

Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)Angle-closure Glaucoma

NCT00762645Alcon Research30

已完成

不适用

Is repeated laser treatment effective in intraocular pressure (IOP) reduction?GlaucomaEye Diseases

ISRCTN67927615St Eriks Eye Hospital (Sweden)40

已完成

3 期

A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI StudyPrimary Open Angle Glaucoma or Ocular Hypertension

NCT02822742Santen Pharmaceutical Co., Ltd.26

已完成

3 期

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%Open-Angle GlaucomaOcular Hypertension

NCT01297920Alcon Research1,062